Oruka Therapeutics, Inc.

ORKA

Held by 4 specialist biotech funds

High Convergence

Share on X

Fund Holdings

4 fund convergence

Avoro Capital Advisors Perceptive Advisors RTW Investments

Position Trend

Feb 17, 2026

$160.3M

3 funds

Mar 16, 2026

$40.4M

1 fund

-75% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 1,333,340Value: $40.4M

# Signal Note: Avoro Capital Initiates $40.4M Position in Oruka Therapeutics Avoro Capital's entry into ORKA signals confidence in the company's pipeline, most notably ORK-001 for localized scleroderma, which completed a Phase 2b trial in 2023. This represents material validation from a specialized biotech investor with strong track record in early-stage therapeutics, though upcoming catalyst timing—likely IND clearance or Phase 3 initiation for ORK-001—will be critical to validate the thesis.

Perceptive AdvisorsNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

CNTA4 funds KYMR4 funds ALKS3 funds SYRE3 funds COGT3 funds MNMD3 funds PTGX3 funds APGE

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

# Signal Note: Perceptive Advisors Initiates $44.8M Position in ORKA Edelman's entry into Oruka signals conviction in the company's lead program, ORK-0119, a Phase 2b OKT3-based immunotherapy for moderate-to-severe atopic dermatitis—a competitive space but one with potential for differentiation via oral dosing. The 1.5M share stake (substantial for a $~400M market cap biotech) suggests confidence in near-term data readouts; timing and efficacy relative to existing agents (dupilumab, JAK inhibitors) will be key catalysts. Edelman's track record on clinical-stage bets warrants attention to clinical progress over the next 12-18 months.